Mesoblast Limited files as an Australian foreign private issuer, and its SEC reports document ASX announcements for its ADR-listed securities. Form 6-K reports incorporate Appendix 4C activity reports, press releases and R&D materials covering Ryoncil commercialization, operating cash spend, clinical programs for rexlemestrocel-L and Ryoncil, FDA regulatory updates and the company’s mesenchymal lineage cell therapy platform.
The filing record also documents capital-structure and governance matters through ASX appendices for proposed and quoted securities, unquoted equity securities, cessation of securities and changes in director interests. These disclosures connect Mesoblast’s public reporting to product revenue, pipeline development, equity issuance and foreign-issuer compliance under Form 20-F reporting.
Mesoblast Limited reported completion of patient treatment in its pivotal randomized controlled Phase 3 MSB-DR004 trial of rexlemestrocel-L for chronic low back pain associated with degenerative disc disease. A total of 350 patients were randomized to receive either an intra-discal injection of rexlemestrocel-L or a sham injection, increased from 300 patients after strong investigator demand.
The primary endpoint is durable pain reduction at 12 months from a single injection, with secondary endpoints including function, quality of life, and reduction or cessation of pain medication, including opioids. The indication is described as having potential peak year revenue of >US$10 billion for Mesoblast at single-digit market penetration. Rexlemestrocel-L holds RMAT designation from the FDA for this indication, allowing eligibility for priority review once a BLA is filed, and top-line trial results are expected in mid-CY2027.
Mesoblast Limited reported preliminary Ryoncil® net revenue of US$36 million for the fourth quarter and US$115 million for the first full year after FDA approval, including US$66.5 million in the second half.
Net operating cash spend for the year was US$43.8 million and US$13.4 million in the second half, leaving US$103 million of cash at June 30, 2026 after drawing US$50 million under a five-year US$125 million credit facility used to extinguish maturing debt obligations. The company advanced its pipeline by enrolling an adult SR-aGvHD registration trial for Ryoncil, receiving IND clearance to proceed directly to a registrational Duchenne muscular dystrophy trial in children, completing treatment of at least 300 patients in a pivotal Phase 3 chronic low back pain study of rexlemestrocel-L, and obtaining an FDA BLA filing number for rexlemestrocel-L in prevention of life-threatening gastrointestinal bleeding in LVAD patients while requesting modular review. Mesoblast also licensed a CAR-MSC technology platform to enhance future cell therapies. Revenue figures are based on management’s initial analysis and remain subject to closing procedures and audit.
Mesoblast Limited reports that Founder and CEO Dr. Silviu Itescu exercised 1,885,334 options on ordinary shares on 17 July 2026, paying the company A$2,733,734 at an exercise price of A$1.45 per share and retaining all newly issued shares.
Following the transaction he holds 80,844,262 Mesoblast shares (69,642,172 direct and 11,202,090 indirect) and 16,311,253 options. Mesoblast develops allogeneic cellular medicines, including FDA‑approved Ryoncil for pediatric steroid‑refractory acute graft versus host disease.
Mesoblast Limited furnished a Form 6-K describing several announcements made to the Australian Securities Exchange on July 14, 2026, including new issue notifications, applications for quotation of securities and a change of director’s interests.
The change notice shows Dr Silviu Itescu had 278,571 options lapse on July 7, 2026 due to a previously achieved duplicative milestone. His holdings remain 78,958,928 ordinary shares (67,756,838 direct; 11,202,090 indirect), while option holdings decreased from 18,475,158 to 18,196,587, with nil consideration paid or received.
Mesoblast Limited reported that it has achieved its target of treating at least 300 patients in MSB-DR004, a pivotal Phase 3 randomized controlled trial of rexlemestrocel-L for chronic low back pain associated with degenerative disc disease. The study is designed to confirm the durable pain reduction from a single intra-discal injection seen in the earlier MSB-DR003 trial, and management states this enrollment level ensures the trial is well powered. Commercial manufacturing is proceeding in parallel so a filing for approval can follow promptly after results.
The primary endpoint measures reduction in low back pain at 12 months versus sham control; secondary endpoints include function, quality of life, and cessation of pain medication, including opioids. The indication is described as a potential blockbuster with potential peak-year revenue of >US$10 billion at single-digit market penetration, addressing over 7 million U.S. patients with chronic low back pain due to inflammatory degenerative disc disease and accounting for approximately 50% of U.S. prescription opioid use. FDA has agreed on the confirmatory trial design and this 12‑month primary endpoint as an approvable indication, and granted Regenerative Medicine Advanced Therapy designation, providing rolling and priority review eligibility for a planned Biologics License Application. Top-line results are expected in mid‑CY2027 after 12‑month follow-up.
Mesoblast highlights broader use of its allogeneic stromal cell platforms, including Ryoncil, described as the first FDA‑approved mesenchymal stromal cell therapy, and reports an intellectual property portfolio of over 1,000 granted patents or applications providing commercial protection through at least 2044 in major markets.
Mesoblast Ltd reported that Chief Financial Officer James Michael O'Brien received a grant of 650,000 options to acquire Ordinary Shares. The options have an exercise price of A$2.90 per share, expire on December 22, 2032, and vest only if Mr. O'Brien achieves specified milestones.
Mesoblast Limited reported preliminary net revenue from Ryoncil® (remestemcel-L-rknd) of US$36 million for the fourth quarter and US$115 million for the first full year ended June 30, 2026. Management highlights strong uptake since launch and states that revenues have already exceeded initial projections.
The company expects continued revenue growth in the coming fiscal year, citing momentum across major U.S. pediatric centers, and describes its capital position as strong with operational activities well funded through revenue growth and a new five-year facility. Ryoncil® is described as the first FDA-approved mesenchymal stromal cell therapy and the only approved product for children under 12 with steroid-refractory acute graft-versus-host disease. The revenue figures are based on preliminary estimates and remain subject to customary year-end closing and audit procedures.
Mesoblast Limited reports a key regulatory step for its investigational cell therapy rexlemestrocel-L in end-stage heart failure patients supported by left ventricular assist devices (LVADs). The company has received a Biologics License Application (BLA) filing number from the U.S. Food and Drug Administration and has requested a modular review of the BLA for preventing life-threatening gastrointestinal bleeding linked to right ventricular dysfunction.
Rexlemestrocel-L, an allogeneic mesenchymal precursor cell therapy, holds both Regenerative Medicine Advanced Therapy and Orphan Drug designations in this LVAD population, potentially allowing rolling and priority review. Mesoblast highlights recent FDA draft guidance emphasizing regulatory flexibility for serious rare diseases, while positioning rexlemestrocel-L within a broader pipeline that includes the already FDA-approved Ryoncil for pediatric steroid-refractory acute graft versus host disease.
Mesoblast Limited has drawn down US$50 million from a five-year, non-dilutive credit facility provided by existing shareholder and director Dr. Gregory George. Together with US$122 million of cash as of March 30, 2026, this strengthens funding for commercial operations and its growth pipeline.
The new facility carries a fixed interest rate of 8.00% per annum with a five-year interest-only period and can be repaid at any time without prepayment or exit fees. It is secured solely by the Temcell royalty, leaving Mesoblast’s other material assets and intellectual property unencumbered.
Mesoblast Limited highlights progress as a global leader in allogeneic, off‑the‑shelf cellular medicines. Its first FDA‑approved product RYONCIL has generated net revenue exceeding US$100M since launch, with Q3 FY26 gross revenue of US$35M and net revenue of US$30M.
RYONCIL produced gross profit of US$44M in 1H FY26, against direct selling costs of US$7M. Net operating cash spend in Q3 FY26 was US$4M, supported by receipts of US$34.6M, and cash was US$122M at March 31, 2026. A new US$125M term loan replaces higher‑cost debt.
The company is funding an extensive pipeline, including Phase 3 programs for chronic low back pain and chronic heart failure using rexlemestrocel‑L, and label‑extension studies for RYONCIL in adult steroid‑refractory acute graft versus host disease and pediatric Duchenne muscular dystrophy. Mesoblast is also advancing next‑generation gene‑modified MSC platforms such as CAR‑MSCs and OV‑MSCs for new indications.